Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine d3 and serotonin 5-HT 1A and 5-HT2A receptors: Design, synthesis, and effects on behavior

Journal of Medicinal Chemistry

Volumn 52, Issue 1, 2009, Pages 151-169

  Butini, Stefania ^a   Gemma, Sandra ^a   Campiani, Giuseppe ^a   Franceschini, Silvia ^a   Trotta, Francesco ^a   Borriello, Marianna ^a,b   Ceres, Nicoletta ^a,b   Ros, Sindu ^a   Coccone, Salvatore Sanna ^a   Bernetti, Matteo ^a   De Angelis, Meri ^a   Brindisi, Margherita ^a   Nacci, Vito ^a   Fiorini, Isabella ^a   Novellino, Ettore ^a,b   Cagnotto, Alfredo ^a,c   Mennini, Tiziana ^a,c   Sandager Nielsen, Karin ^d   Andreasen, Jesper Tobias ^d   Scheel Kruger, Jorgen ^d   Mikkelsen, Jens D ^e   Fattorusso, Caterina ^a,b   more..

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d NEUROSEARCH A S   (Denmark)

^e Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

3 [5 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]PENTYLOXY]ISOQUINOLINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 3 RECEPTOR; HALOPERIDOL; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUTYL] 3,4 DIHYDROPYRAZINO[1,2 A]INDOL 1(2H) ONE; N [4 [4 (3 CHLOROPHENYL)PIPERAZIN 1 YL]BUTYL]ISOQUINOLINE 3 CARBOXAMIDE; N [4 [4 (3 TOLYL)PIPERAZIN 1 YL]BUTYL]BENZO[B]FURAN 2 CARBOXAMIDE; POTASSIUM CHANNEL HERG; SERANASE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG; LIGAND; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG DESIGN; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERACTIVITY; LIMBIC CORTEX; MALE; MESOCORTICOLIMBIC AREA; MOUSE; NONHUMAN; ONCOGENE C FOS; RAT; REACTION ANALYSIS; RECEPTOR AFFINITY; ANIMAL; ANIMAL BEHAVIOR; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; DRUG SCREENING; METABOLISM; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BINDING SITES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; LIGANDS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 59449085290     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800689g     Document Type: Article

References (77)

1. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am. J. Psychiatry 1997, 154,1-63.
2. Carlsson, A. The current status of the dopamine hypothesis of schizophrenia. Neurovsychovharmacology 1988, 1, 179-186.
3. Meltzer, H. Y. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psy-chovharmacology (Berlin) 1989, 99, S18-S27.
4. Campbell, M.; Young, P. I.; Bateman, D. N.; Smith, J. M.; Thomas, S. H. The use of atypical antipsychotics in the management of schizophrenia. Br. J. Clin. Pharmacol. 1999, 47, 13-22.
5. Koller, E. A.; Doraiswamy, P. M. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002, 22, 841-852.
6. Geddes, J.; Freemantle, N.; Harrison, P.; Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med. J. 2000, 321, 1371-1376.
7. McGawin, J. K.; Goa, K. L. Aripiprazole. CNS Drugs 2002, 16, 779-786.
8. Buckley, P. F. Aripiprazole: Efficacy and Tolerability Profile of a Novel-Acting Atypical Antipsychotic. Drugs Today 2003, 2, 145-151.
9. Butini, S.; Campiani, G.; De Angelis, M.; Fattorusso, C.; Nacci, V.; Fiorini, I. Novel antipsychotic agents: recent advances in the drug treatment of schizophrenia. Expert Ovin. Ther. Patents 2003,13, 425-448.
10. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005, 48, 6523-6543.
11. Zhong, P.; Yuen, E. Y.; Yan, Z. Modulation of Neuronal Excitability by Serotonin-NMDA Interactions in Prefrontal Cortex. Mool CelL Neurosci. 2008, 38, 290-299.
12. 1A receptors in human brain tissue. Eur. J. Pharmacol. 1992, 221, 397-398.
13. 1A receptors in human post-mortem brain. Eur. J. Pharmacol. 1999, 386, 313-315.
14. (c) Richelson, E.; Souder, T. Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci. 2000, 68, 29-39.
15. Yoshida, K.; Sugita, T.; Higuchi, H.; Hishikawa, Y. Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms. Eur. Psychiatry 1998, 13, 421-422.
16. Christoffersen, C. L.; Meltzer, L. T. Reversal of haloperidol-induced extrapiramidal side effects in cebus monkeys by 8-hydroxy-2-(di-N- propylamino)tetralin and its enantiomers. Neurovsychovharmacology 1998, 18, 399-402.
17. 1A receptors. J. Pharmacol. Exv. Ther. 2000, 295, 853-861.
18. 1A receptor agonist LY293284 in the drug discrimination assay in rats. Psychovharmacology (Berlin) 2004,172, 415-421.
19. 1A receptor. Eur. J. Pharmacol. 2002, 441, 137-140.
20. 1A receptor agonist BAY X 3702 in vitro and in vivo. Brain Res. 2001, 888, 150-157.
21. 1A receptors improve cognition in schizophrenia. Behav. Brain Res. 2008,195, 98-102.
22. 3 receptor in schizophrenia and in antipsychotic drug actions. Brain Res. Brain Res. Rev. 2000, 31, 277-287.
23. 3 receptor antagonists as therapeutic agents. Drug Discovery Today 2005, 10, 917-925.
24. 2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J. Pharmacol. Exv. Ther. 2008, 324, 1212-1226.
25. (a) Campiani, G.; Nacci, V.; Bechelli, S.; Ciani, S. M.; Garofalo, A.; Fiorini, I.; Wikstrom, H.; de Boer, P.; Liao, Y.; Tepper, P. G.; Cagnotto, A.; Mennini, T. New Antipsychotic Agents with Serotonin and Dopamine Antagonist Properties Based on a Pyrrolo[2,1- b][1,3]benzothiazepine Structure. J. Med. Chem. 1998, 41, 3763-3772.
26. (b) Campiani, G.; Butini, S.; Gemma, S.; Nacci, V.; Fattorusso, C.; Catalanotti, B.; Giorgi, G.; Cagnotto, A.; Goegan, M.; Mennini, T.; Minetti, P.; Di Cesare, M. A.; Mastroianni, D.; Scafetta, N.; Galletti, B.; Stasi, M. A.; Castorina, M.; Pacifici, L.; Ghirardi, O.; Tinti, O.; Carminati, P. Pyrrolo[1,3]benzothiazepine atypical antipsychotic agents. Synthesis, structure-activity relationships, molecular-modelling, and biological studies. J. Med. Chem. 2002, 45, 344-359.
27. (c) Campiani, G.; Butini, S.; Fattorusso, C.; Catalanotti, B.; Gemma, S.; Nacci, V.; Morelli, E.; Cagnotto, A.; Mereghetti, I.; Mennini, T.; Carli, M.; Minetti, P.; Di Cesare, M. A.; Mastroianni, D.; Scafetta, N.; Galletti, B.; Stasi, M. A.; Castorina, M.; Pacifici, L.; Vertechy, M.; Di Serio, S.; Ghirardi, O.; Tinti, O.; Carminati, P. Pyrrolo[1,3]benzothiazepine- based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. J. Med. Chem. 2004, 47, 143-157.
28. (d) Campiani, G.; Butini, S.; Fattorusso, C.; Trotta, F.; Gemma, S.; Catalanotti, B.; Nacci, V.; Fiorini, I.; Cagnotto, A.; Mereghetti, I.; Mennini, T.; Minetti, P.; Di Cesare, M. A.; Stasi, M. A.; Di Serio, S.; Ghirardi, O.; Tinti, O.; Carminati, P. Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. J. Med. Chem. 2005, 48, 1705-1708.
29. 2 receptors. J. Med. Chem. 2003, 46, 3822-3839.
30. Suzuki, H.; Gyoutoku, H.; Yokoo, H.; Shinba, M.; Sato, Y.; Yamada, H.; Murakami, Y. Unexpected formation of quinolone derivatives in Reissert indole synthesis. Synlett 2000, 8, 1196-1199.
31. Rajur, S. B.; Merwade, A. Y.; Flendi, S. B.; Basanagoudar, I. D. Synthesis of 1,2,3,4-tetrahydropyrazino[1,2-a]indoles and ethyl 1-(2- amino-ethyl)indole-2-carboxylates. Indian J. Chem. 1989, 28B, 1065-1068.
32. Repke, D. B., III. Synthesis of 5-methoxy-and 5-hydroxy-1,2,3,4- tetrahydro-9H-pyrido[3,4-b]indoles. J. Heterocycl. Chem. 1982, 19, 845-848.
33. Sugimoto, O.; Mori, M.; Moriya, K.; Tanji, K. Application of phosphonium salts to the reactions of various kinds of amides. Helv. Chim. Acta 2001, 84, 1112-1118.
34. Robertson, A. A. B.; Botting, N. P. Synthesis of deuterium labelled desulfoglucosinolates as internal standards for LC-MS analysis. Tetrahedron 1999, 55, 13269-13284.
35. GPCR alignments; www.bioinfo-pharma.u-strasbg.fr/gpcrdb/jss.html.
36. Terakita, A. The opsins. Genome Biol. 2005, 6, 213.
37. Gether, U.; Kobilka, B. K. G protein-coupled receptors. II. Mechanism of agonist activation. J. Biol. Chem. 1998, 273, 17979-17982.
38. Ballesteros, J. A.; Jensen, A. D.; Liapakis, G.; Rasmussen, S. G.; Shi, L.; Gether, U.; Javitch, J. A. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J. Biol. Chem. 2001, 276, 29171-29177.
39. Shapiro, D. A.; Kristiansen, K.; Weiner, D. M.; Kroeze, W. K.; Roth, B.L. Evidence for a model of agonist-induced activation of 5-hy-droxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J. Biol. Chem. 2002, 277, 11441-11449.
40. Schwartz, T. W.; Frimurer, T. M.; Holst, B.; Rosenkilde, M. M.; Elling, C.E. Molecular mechanism of 7TM receptor activation-a global toggle switch model. Annu. Rev. Pharmacol. Toxicol. 2006, 46, 481-519.
41. Shi, L.; Javitch, J. A. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467.
42. Javitch, J. A.; Ballesteros, J. A.; Weinstein, H.; Chen, J. A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. Biochemistry 1998, 37, 998-1006.
43. Rasmussen, S. G.; Choi, H. J.; Rosenbaum, D. M.; Kobilka, T. S.; Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R.; Sanishvili, R.; Fischetti, R. F.; Schertler, G. F.; Weis, W. I.; Kobilka, B. K. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007, 450, 383-387.
44. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318, 1258-1265.
45. Rosenbaum, D. M.; Cherezov, V.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Yao, X. J.; Weis, W. I.; Stevens, R. C.; Kobilka, B. K. GPCR engineering yields high- resolution structural insights into beta2-adrenergic receptor function. Science 2007, 318, 1266-1273.
46. Kalani, M. Y.; Vaidehi, N.; Hall, S. E.; Trabanino, R. J.; Freddolino, P. L.; Kalani, M. A.; Floriano, W. B.; Kam, V. W.; Goddard, W. A., 3rd. The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 3815-3820.
47. Roth, B. L.; Shoham, M.; Choudhary, M. S.; Khan, N. Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors. Mol. Pharmacol. 1997, 52, 259-266.
48. 3 receptor ligands: structure-activity relationships and selected neu- ropharmacological aspects. Pharmacol Ther. 2006, 112, 281-333.
49. Boess, F. G., Jr.; Meyer, V.; Zwingelstein, C.; Sleight, A. J. Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor. Mol. Pharmacol. 1997, 52, 515-523.
50. Shapiro, D. A.; Kristiansen, K.; Kroeze, W. K.; Roth, B. L. Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol. Pharmacol. 2000, 58, 877-886.
51. Johnson, M. P.; Loncharich, R. J.; Baez, M.; Nelson, D. L. Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol. Pharmacol. 1994, 45, 277-286.
52. 2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. Mol. Pharmacol. 1996, 50, 34-42.
53. Recanatini, M.; Cavalli, A.; Masetti, M. Modeling hERG and its Interactions with Drugs: Recent Advances in Light of Current Potassium Channel Simulations. ChemMedChem. 2008, 3, 523-535.
54. Stansfeld, P. J.; Gedeck, P.; Gosling, M.; Cox, B.; Mitcheson, J. S.; Sutcliffe, M. J. Drug block of the hERG potassium channel: insight from modelling. Proteins 2007, 68, 568-580.
55. Farid, R.; Day, T.; Friesner, R. A.; Pearlstein, R. A. New insights about hERG blockade obtained from protein modeling, potential energy mapping, and docking studies. Bioorg. Med. Chem. 2006, 14, 3160-3173.
56. Kamiya, K.; Niwa, R.; Mitcheson, J. S.; Sanguinetti, M. C. Molecular determinants of hERG channel block. Mol. Pharmacol. 2006, 69, 1709-1716.
57. Myokai, T.; Ryu, S.; Shimizu, H.; Oiki, S. Topological mapping of the asymmetric drug binding to the human ether-à-go-go-related gene product (hERG) potassium channel by use of tandem dimers. Mol. Pharmacol. 2008, 73, 1643-1651.
58. Pearlstein, R. A.; Vaz, R. J.; Kang, J.; Chen, X. L.; Preobrazhenskaya, M.; Shchekotikhin, A. E.; Korolev, A. M.; Lysenkova, L. N.; Miroshnikova, O. V.; Hendrix, J.; Rampe, D. Characterization of hERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett. 2003,13, 1829-1835.
59. Cavalli, A.; Poluzzi, E.; De Ponti, F.; Recanatini, M. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of hERG K(+) channel blockers. J. Med. Chem. 2002, 45, 3844-3853.
60. 1a receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neuro- chem. 2001, 76, 1521-1531.
61. 2A receptors. Eur. J. Pharmacol. 1995, 280, R9-R11.
62. (b) Gleason, S. D.; Shannon, H. E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berlin) 1997, 129, 79-84.
63. (a) Deutch, A. Y.; Lee, M. C.; Iadarola, M. J. Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol. Cell. Neurosci. 1992, 3, 332-341. (b) Robertson, G. S.; Fibiger, H. C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 1992, 46, 315-328.
64. Tremblay, P. O.; Gervais, J.; Rouillard, C. Modification of haloperidol- induced pattern of c-fos expression by serotonin agonists. Eur. J. Neurosci. 1998, 10, 3546-3555.
65. Robertson, G. S.; Matsumura, H.; Fibiger, H. C. Induction Patterns of Fos-Like Immunoreactivity in the Forebrain as Predictors of Atypical Antipsychotic Activity. J Pharmacol Exp Ther. 1994, 271, 1058-1066.
66. Sumner, B. E.; Cruise, L. A.; Slattery, D. A.; Hill, D. R.; Shahid, M.; Henry, B. Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs. Psychopharmacology (Berlin) 2004, 171, 306-321.
67. Belfield, A. J.; Brown, G. R.; Foubister, A. J.; Ratcliffe, P. D. Synthesis of meta-substituted aniline derivatives by nucleophilic substitution. Tetrahedron 1999, 55, 13285-13300.
68. Butini, S.; Campiani, G.; Borriello, M.; Gemma, S.; Panico, A.; Persico, M.; Catalanotti, B.; Ros, S.; Brindisi, M.; Agnusdei, M.; Fiorini, I.; Nacci, V.; Novellino, E.; Belinskaya, T.; Saxena, A.; Fattorusso, C. Exploiting Protein Fluctuations at the Active-Site Gorge of Human Cholinesterases: Further Optimization of the Design Strategy to Develop Extremely Potent Inhibitors. J. Med. Chem. 2008, 51, 3154-3170.
69. Ding, H. Q.; Karasawa, N.; Goddard, W. A III atomic level simulations on a million particles: the cell multipole method for Coulomb and London nonbond interactions. J. Chem. Phys. 1992, 97, 4309-4315.
70. Dauber-Osguthorpe, P.; Roberts, V. A.; Osguthorpe, D. J.; Wolff, J.; Genest, M.; Hagler, A. T. Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins 1988, 4, 31-47.
71. Maple, J. R.; Hwang, M. J.; Stockfisch, T. P.; Dinur, U.; Waldman, M.; Ewig, C. S.; Hagler, A. T. Derivation of class II force fields. I. Methodology and quantum force field for the alkyl functional group and alkane molecules. J Comput Chem. 1994, 15, 162-182.
72. Stewart, J. P. MOPAC; Stewart Computational Chemistry: Colorado Springs, CO, 2007; http://OpenMOPAC.net.
73. 3H]-mepyramine binding sites in guinea pig cerebellum and lung. Agents Actions 1991, 33, 181-184.
74. DeLean, K. W.; Munson, P. J.; Rodbard, D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay and physiological dose-response curves. Am. J. Physiol. 1978, 235, E97-E102.
75. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
76. Hansen, H. H.; Timmermann, D. B.; Peters, D.; Walters, C.; Damaj, M. I.; Mikkelsen, J. D. Alpha-7 nicotinic acetylcholine receptor agonists selectively activate limbic regions of the rat forebrain: an effect similar to antipsychotics. J. Neurosci. Res. 2007, 85, 1810-1818.
77. Mikkelsen, J. D.; Vrang, N.; Mrosovsky, N. Expression of Fos in the circadian system following nonphotic stimulation. Brain Res. Bull. 1998, 47, 367-376.